Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy

enthalten in: Neuromuscular disorders | 2015

von Lynn, S. | Aartsma-Rus, A. | Bushby, K. | +13

Enhancing translation: Guidelines for standard pre-clinical experiments in mdx mice

enthalten in: Neuromuscular disorders | 2012

von Willmann, R. | De Luca, A. | Benatar, M. | +4

Searching for novel anti-myotonic agents: Pharmacophore requirement for use-dependent block of skeletal muscle sodium channels by N-benzylated cyclic derivatives of tocainide

enthalten in: Neuromuscular disorders | 2012

von De Luca, A. | De Bellis, M. | Corbo, F. | +5

New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse

enthalten in: Neuromuscular disorders | 2004

von De Luca, A. | Pierno, S. | Liantonio, A. | +6

Pre-clinical trials in Duchenne dystrophy: what animal models can tell us about potential drug effectiveness

enthalten in: Neuromuscular disorders | 2002

von De Luca, A. | Pierno, S. | Liantonio, A. | +1

Ion channels in muscle and cardiac hereditary diseases: from gene dysfunction to pharmacological therapy - 10-11 March 2000, Bari, Italy

enthalten in: Neuromuscular disorders | 2001

von Desaphy, J. | De Luca, A. | Tricarico, D. | +2